scholarly journals Recent Advances in Stem Cell Therapies to Address Neuroinflammation, Stem Cell Survival, and the Need for Rehabilitative Therapies to Treat Traumatic Brain Injuries

2021 ◽  
Vol 22 (4) ◽  
pp. 1978
Author(s):  
George R. Bjorklund ◽  
Trent R. Anderson ◽  
Sarah E. Stabenfeldt
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Brain Injuries ◽  
The United States ◽  
Traumatic Brain Injuries ◽  
Post Injury ◽  
Stem Cell Therapies ◽  
Neuroprotective Effects ◽  
Cell Therapies ◽  
Severe Tbi

Traumatic brain injuries (TBIs) are a significant health problem both in the United States and worldwide with over 27 million cases being reported globally every year. TBIs can vary significantly from a mild TBI with short-term symptoms to a moderate or severe TBI that can result in long-term or life-long detrimental effects. In the case of a moderate to severe TBI, the primary injury causes immediate damage to structural tissue and cellular components. This may be followed by secondary injuries that can be the cause of chronic and debilitating neurodegenerative effects. At present, there are no standard treatments that effectively target the primary or secondary TBI injuries themselves. Current treatment strategies often focus on addressing post-injury symptoms, including the trauma itself as well as the development of cognitive, behavioral, and psychiatric impairment. Additional therapies such as pharmacological, stem cell, and rehabilitative have in some cases shown little to no improvement on their own, but when applied in combination have given encouraging results. In this review, we will abridge and discuss some of the most recent research advances in stem cell therapies, advanced engineered biomaterials used to support stem transplantation, and the role of rehabilitative therapies in TBI treatment. These research examples are intended to form a multi-tiered perspective for stem-cell therapies used to treat TBIs; stem cells and stem cell products to mitigate neuroinflammation and provide neuroprotective effects, biomaterials to support the survival, migration, and integration of transplanted stem cells, and finally rehabilitative therapies to support stem cell integration and compensatory and restorative plasticity.

scholarly journals Perspective in optimization of stem cell therapies for heart regeneration

2017 ◽  
Vol 71 (0) ◽  
pp. 0-0 ◽  
Author(s):  
Paulina Gapska ◽  
Maciej Kurpisz
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Free Cell ◽  
Vector System ◽  
Heart Regeneration ◽  
Cell Sheets ◽  
Stem Cell Therapies ◽  
Cell Therapies ◽  
Stem Cell Source ◽  
Teratoma Formation

There is a variety of mechanisms(s) factor(s) that may influence stem cell therapies for heart regeneration. Among the best candidates for stem cell source are: mesenchymal stem cells (also those isolated from adipose tissue), cardiac cell progenitors (CPC) and descendants of iPSC cells. iPSC/s can be potentially beneficial although their pluripotent induction has been still in question due to: low propagation efficacy, danger of genomic integration/instability, biological risk of current vector system teratoma formation etc. which have been discussed in this review. Optimization protocols are required in order to enhance stem cells resistance to pathological conditions that they may encounter in pathological organ and to increase their retention. Combination between gene transfer and stem cell therapy is now more often used in pre-clinical studies with the prospect of subsequent clinical trials. Complementary substances have been contemplated to support stem cell viability (mainly anti-inflammatory and anti- apoptotic agents), which have been tested in animal models with promising results. Integration of nanotechnology both for efficient stem cell imaging as well as with the aim to provide cell supporting scaffolds seem to be inevitable for further development of cellular therapies. The whole organ (heart) reconstruction as well as biodegradable scaffolds and scaffold-free cell sheets have been also outlined.

scholarly journals Targeting Programmed Cell Death to Improve Stem Cell Therapy: Implications for Treating Diabetes and Diabetes-Related Diseases

2021 ◽  
Vol 9 ◽  
Author(s):  
Qi Zhang ◽  
Xin-xing Wan ◽  
Xi-min Hu ◽  
Wen-juan Zhao ◽  
Xiao-xia Ban ◽  
...  
Keyword(s):  
Stem Cells ◽  
Cell Death ◽  
Stem Cell ◽  
Programmed Cell Death ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Therapeutic Effects ◽  
Stem Cell Therapies ◽  
Cell Therapies ◽  
Wide Range

Stem cell therapies have shown promising therapeutic effects in restoring damaged tissue and promoting functional repair in a wide range of human diseases. Generations of insulin-producing cells and pancreatic progenitors from stem cells are potential therapeutic methods for treating diabetes and diabetes-related diseases. However, accumulated evidence has demonstrated that multiple types of programmed cell death (PCD) existed in stem cells post-transplantation and compromise their therapeutic efficiency, including apoptosis, autophagy, necroptosis, pyroptosis, and ferroptosis. Understanding the molecular mechanisms in PCD during stem cell transplantation and targeting cell death signaling pathways are vital to successful stem cell therapies. In this review, we highlight the research advances in PCD mechanisms that guide the development of multiple strategies to prevent the loss of stem cells and discuss promising implications for improving stem cell therapy in diabetes and diabetes-related diseases.

scholarly journals Intravenous Cardiac Stem Cell-Derived Exosomes Ameliorate Cardiac Dysfunction in Doxorubicin Induced Dilated Cardiomyopathy

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Adam C. Vandergriff ◽  
James Bizetto Meira de Andrade ◽  
Junnan Tang ◽  
M. Taylor Hensley ◽  
Jorge A. Piedrahita ◽  
...  
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Dilated Cardiomyopathy ◽  
Immune Reaction ◽  
Heart Function ◽  
Cardiac Stem Cells ◽  
Systemic Delivery ◽  
Stem Cell Therapies ◽  
Cell Therapies ◽  
Immunocompetent Mice

Despite the efficacy of cardiac stem cells (CSCs) for treatment of cardiomyopathies, there are many limitations to stem cell therapies. CSC-derived exosomes (CSC-XOs) have been shown to be responsible for a large portion of the regenerative effects of CSCs. Using a mouse model of doxorubicin induced dilated cardiomyopathy, we study the effects of systemic delivery of human CSC-XOs in mice. Mice receiving CSC-XOs showed improved heart function via echocardiography, as well as decreased apoptosis and fibrosis. In spite of using immunocompetent mice and human CSC-XOs, mice showed no adverse immune reaction. The use of CSC-XOs holds promise for overcoming the limitations of stem cells and improving cardiac therapies.

scholarly journals Stem cell therapies for acute spinal cord injury in humans: a review

2019 ◽  
Vol 46 (3) ◽  
pp. E10 ◽  
Author(s):  
Michael C. Jin ◽  
Zachary A. Medress ◽  
Tej D. Azad ◽  
Vanessa M. Doulames ◽  
Anand Veeravagu
Keyword(s):  
Spinal Cord ◽  
Stem Cells ◽  
Spinal Cord Injury ◽  
Stem Cell ◽  
Cell Biology ◽  
Stem Cell Biology ◽  
Stem Cell Therapies ◽  
Cell Therapies ◽  
Recent Advances ◽  
Cord Injury

Recent advances in stem cell biology present significant opportunities to advance clinical applications of stem cell–based therapies for spinal cord injury (SCI). In this review, the authors critically analyze the basic science and translational evidence that supports the use of various stem cell sources, including induced pluripotent stem cells, oligodendrocyte precursor cells, and mesenchymal stem cells. They subsequently explore recent advances in stem cell biology and discuss ongoing clinical translation efforts, including combinatorial strategies utilizing scaffolds, biogels, and growth factors to augment stem cell survival, function, and engraftment. Finally, the authors discuss the evolution of stem cell therapies for SCI by providing an overview of completed (n = 18) and ongoing (n = 9) clinical trials.

scholarly journals Combating Osteoarthritis through Stem Cell Therapies by Rejuvenating Cartilage: A Review

2018 ◽  
Vol 2018 ◽  
pp. 1-13 ◽  
Author(s):  
Navneet Kumar Dubey ◽  
Viraj Krishna Mishra ◽  
Rajni Dubey ◽  
Shabbir Syed-Abdul ◽  
Joseph R. Wang ◽  
...  
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Growth Factors ◽  
Articular Cartilage ◽  
Current Status ◽  
Self Healing ◽  
Mechanical Stimuli ◽  
Stem Cell Therapies ◽  
Differentiation Potential ◽  
Cell Therapies

Knee osteoarthritis (OA) is a chronic degenerative disorder which could be distinguished by erosion of articular cartilage, pain, stiffness, and crepitus. Not only aging-associated alterations but also the metabolic factors such as hyperglycemia, dyslipidemia, and obesity affect articular tissues and may initiate or exacerbate the OA. The poor self-healing ability of articular cartilage due to limited regeneration in chondrocytes further adversely affects the osteoarthritic microenvironment. Traditional and current surgical treatment procedures for OA are limited and incapable to reverse the damage of articular cartilage. To overcome these limitations, cell-based therapies are currently being employed to repair and regenerate the structure and function of articular tissues. These therapies not only depend upon source and type of stem cells but also on environmental conditions, growth factors, and chemical and mechanical stimuli. Recently, the pluripotent and various multipotent mesenchymal stem cells have been employed for OA therapy, due to their differentiation potential towards chondrogenic lineage. Additionally, the stem cells have also been supplemented with growth factors to achieve higher healing response in osteoarthritic cartilage. In this review, we summarized the current status of stem cell therapies in OA pathophysiology and also highlighted the potential areas of further research needed in regenerative medicine.

scholarly journals Derivation of Induced Pluripotent Stem Cells from the Baboon: A Nonhuman Primate Model for Preclinical Testing of Stem Cell Therapies

2013 ◽  
Vol 15 (6) ◽  
pp. 495-502 ◽  
Author(s):  
Christopher S. Navara ◽  
Jacey Hornecker ◽  
Douglas Grow ◽  
Shital Chaudhari ◽  
Peter J. Hornsby ◽  
...  
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Nonhuman Primate ◽  
Pluripotent Stem Cells ◽  
Stem Cell Therapies ◽  
Nonhuman Primate Model ◽  
Primate Model ◽  
Preclinical Testing ◽  
Cell Therapies ◽  
Induced Pluripotent

scholarly journals Cardiomyocyte Death and Genome-Edited Stem Cell Therapy for Ischemic Heart Disease

2021 ◽  
Author(s):  
Hyun-Min Cho ◽  
Je-Yoel Cho
Keyword(s):  
Stem Cells ◽  
Cell Death ◽  
Stem Cell ◽  
Heart Disease ◽  
Cell Therapy ◽  
Ischemic Heart Disease ◽  
Genome Editing ◽  
Stem Cell Therapy ◽  
Stem Cell Therapies ◽  
Cell Therapies

AbstractMassive death of cardiomyocytes is a major feature of cardiovascular diseases. Since the regenerative capacity of cardiomyocytes is limited, the regulation of their death has been receiving great attention. The cell death of cardiomyocytes is a complex mechanism that has not yet been clarified, and it is known to appear in various forms such as apoptosis, necrosis, etc. In ischemic heart disease, the apoptosis and necrosis of cardiomyocytes appear in two types of programmed forms (intrinsic and extrinsic pathways) and they account for a large portion of cell death. To repair damaged cardiomyocytes, diverse stem cell therapies have been attempted. However, despite the many positive effects, the low engraftment and survival rates have clearly limited the application of stem cells in clinical therapy. To solve these challenges, the introduction of the desired genes in stem cells can be used to enhance their capacity and improve their therapeutic efficiency. Moreover, as genome engineering technologies have advanced significantly, safer and more stable delivery of target genes and more accurate deletion of genes have become possible, which facilitates the genetic modification of stem cells. Accordingly, stem cell therapy for damaged cardiac tissue is expected to further improve. This review describes myocardial cell death, stem cell therapy for cardiac repair, and genome-editing technologies. In addition, we introduce recent stem cell therapies that incorporate genome-editing technologies in the myocardial infarction model.

scholarly journals Trends of Stem Cell Therapies in Age-Related Macular Degeneration

2021 ◽  
Vol 10 (8) ◽  
pp. 1785
Author(s):  
Tadao Maeda ◽  
Sunao Sugita ◽  
Yasuo Kurimoto ◽  
Masayo Takahashi
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Macular Degeneration ◽  
Cell Transplantation ◽  
New Technologies ◽  
Retinal Pigment ◽  
Age Related Macular Degeneration ◽  
Stem Cell Therapies ◽  
Cell Therapies ◽  
Age Related

Age-related macular degeneration (AMD) is a highly prevalent irreversible impairment in the elderly population worldwide. Stem cell therapies have been considered potentially viable for treating AMD through the direct replacement of degenerated cells or secretion of trophic factors that facilitate the survival of existing cells. Among them, the safety of pluripotent stem cell-derived retinal pigment epithelial (RPE) cell transplantation against AMD, and some hereditary retinal degenerative diseases, has been discussed to a certain extent in clinical studies of RPE cell transplantation. Preparations are in progress for its clinical application. On the other hand, clinical trials using somatic stem cells are also being conducted, though these had controversial outcomes. Retinal regenerative medicine using stem cells is expected to make steady progress toward practical use while new technologies are incorporated from various fields, thereby making the role of ophthalmologists in this field increasingly important.

Sign in / Sign up

Export Citation Format

Share Document